CD8A and neoplasm: In this study, we found that single-dose 20 Gy RT increased CD25 and, to a lesser extent, also CD122 on tumor-infiltrating CD8+ T cells, which allowed us to combine this RT scheme with a CD25-biased (made with UFKA-20 mAb) and a CD122-biased IL-2cx (using NARA1 mAb).